MedTrace Logo

A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects

NCT01081704 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-05-28

No results posted yet for this study

Summary

A study of the pharmacokinetics of ustekinumab in Chinese male subjects.

Conditions

  • Healthy

Interventions

DRUG

ustekinumab

Single dose of 45 mg subcutaneous injection

DRUG

ustekinumab

Single dose of 90 mg subcutaneous injection

Sponsors & Collaborators

  • Centocor, Inc.

    lead INDUSTRY

Principal Investigators

  • Centocor, Inc. Clinical Trial · Centocor, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01081704 on ClinicalTrials.gov